One of the most aggressive brain tumors, glioblastoma multiforme, remains a major challenge due to its resistance to conventional therapies and high recurrence rates. The LabsinLove spin-off, created by scientists from the ICMAB-CSIC and the University of Granada, aims to revolutionize its treatment using Boron Neutron Capture Therapy (BNCT).

Rosario Nuñez and Miquel Nuez, scientists at the ICMAB-CSIC and cofounders of spin-off LabsinLove

The boron neutron capture therapy involves linking boron clusters to specific molecules that selectively accumulate in tumor cells. Upon neutron irradiation, these boron-loaded cells undergo localized destruction without harming surrounding healthy tissue.

"This technology allows us to specifically load a cell with many boron atoms, significantly reducing the drug dose needed," explains Miquel Nuez, researcher at LabsinLove. “Moreover, the architecture of these molecules lets us add functional groups, making it easier to track drug accumulation in the tumor using imaging techniques” adds Rosario Núñez, co-founder of LabsinLove and researcher of the Inorganic Materials & Catalysis Group at the Institute of Materials Science of Barcelona (ICMAB-CSIC).

Unlike current treatment options, BNCT reduces drug dosage while maintaining high efficacy, minimizing side effects. Additionally, these molecules are designed to be detectable via imaging techniques, allowing real-time monitoring of drug accumulation in tumors—turning BNCT into a powerful theranostic (therapy + diagnostics) tool.

Researchers from ICMAB-CSIC and the University of Granada participate in the LabsinLove spin-off. At ICMAB, researchers focus on synthesizing these boron-based molecules, while biologists in Granada conduct cell studies and neutron irradiation experiments. This multidisciplinary partnership enhances the translational potential of BNCT for glioblastoma treatment.

Communication ICMAB